Harrow, Inc.: acquires TYRVAYA assets for $30,000,000

What happened

• The filing says Harrow, Inc. completed the acquisition of the Acquired Assets related to TYRVAYA® (varenicline solution) nasal spray from Viatris Inc. on Oct 1, 2026, and paid $30,000,000 in cash.
• The filing says Harrow and Viatris amended and restated the Aug 3, 2026 Asset Purchase Agreement on Oct 1, 2026, and that Viatris retains the rights to commercialize TYRVAYA in Japan; the cash consideration at closing was fixed at $30,000,000.
• The filing says Harrow issued a press release on Oct 5, 2026, announcing the completion of the acquisition.

Key details

• Harrow acquired rights to TYRVAYA in all countries other than Japan and assumed specified liabilities relating to the Acquired Assets.
• The Acquired Assets include the new drug application and other regulatory approvals, intellectual property, technology, inventory and related contracts.
• Harrow is obligated to pay Viatris up to $70,000,000 in contingent milestone payments upon achievement of specified net sales thresholds for TYRVAYA through measurement periods ending on or before Dec 31, 2029.
• The parties entered ancillary agreements, including a transition services agreement, intellectual property assignment agreements and a side letter under which Viatris will pay Harrow tiered royalties on annual net sales of TYRVAYA in Japan and the parties agreed to negotiate a collaboration or similar agreement for Japan.

Why it may matter

• The filing reports Item 1.01 (entry into a material definitive agreement), Item 2.01 (completion of acquisition or disposition of assets) and Item 7.01 (regulation FD disclosure); these items cover the amended and restated purchase agreement, the closing of the acquisition and related disclosure.
• The filing does not show why the company acted.